Alx Oncology Holdings Inc. (ALXO)

Market Closed

1 Sep, 20:00

NASDAQ (NGS)

1. 98

+0.05

+2.5907%

259.71M Market Cap

- P/E Ratio

- Div Yield

1.44M Volume

-3.52 Eps

$ 1.93

Previous Close

Investors:

Add Transaction

Day Range

1.9 2

Year Range

0.96 2.66

Want to track ALXO and more in your Portfolio? 🎯

Get Started For Free

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?

Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.

Zacks | 3 weeks ago

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

Zacks | 3 months ago

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

Seekingalpha | 3 months ago

ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript

Seekingalpha | 6 months ago

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?

Here is how ALX Oncology Holdings Inc. (ALXO) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks | 6 months ago

ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 7 months ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

ALX Oncology Holdings Inc. (NASDAQ:ALXO ) Q2 2025 Earnings Conference Call August 12, 2023 4:30 AM ET Company Participants Alan Bart Sandler - Chief Medical Officer Harish Shantharam - Chief Financial Officer Jason W. Lettmann - CEO & Director Conference Call Participants Allison Marie Bratzel - Piper Sandler & Co., Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Roger Song - Jefferies LLC, Research Division Samuel Evan Slutsky - LifeSci Capital, LLC, Research Division Ting Liu - UBS Investment Bank, Research Division Yu He - H.C.

Seekingalpha | 1 year ago

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks | 1 year ago

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks | 1 year ago

Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for ALX Oncology Holdings (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks | 2 years ago

Blog Affiliate Program About Terms Privacy Help Contact Us